Disease

Overnutrition

Late-stage therapeutic developmentEmerging research

MeSHOvernutrition

Publications

Clinical trials

Related conditions

Associated genes

Related proteins

2025

Latest publication

Current focus

Melanocortin 4 biologyTherapeutic developmentMetabolic & lifestyle factorsDisease mechanisms & pathology

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Reductive stress: The key pathway in metabolic disorders induced by overnutrition.

Research2025-01-11Journal of advanced research

Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited.

Research2004-02-19Arteriosclerosis, thrombosis, and vascular biology

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low

Key developments

1 clinical trial expected to report results, the earliest in Q3 2027.

Upcoming Milestones

Q3 2027A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE RANGING, DOSE-FINDING, UMBRELLA STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08653945 AND PF-08653944, ALONE OR IN COMBINATION, IN ADULTS WITH OVERWEIGHT OR OBESITY (SOLIS-1)

Major developments

Upcoming trial readoutHigh impact

A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE RANGING, DOSE-FINDING, UMBRELLA STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08653945 AND PF-08653944, ALONE OR IN COMBINATION, IN ADULTS WITH OVERWEIGHT OR OBESITY (SOLIS-1)

Results expected Q3 20272026-07-22

Clinical Milestones1View

Results expected 1

2026-07-22A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE RANGING, DOSE-FINDING, UMBRELLA STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08653945 AND PF-08653944, ALONE OR IN COMBINATION, IN ADULTS WITH OVERWEIGHT OR OBESITY (SOLIS-1)Results expected Q3 2027

Activity timeline1

2026-07-22ClinicalA PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE RANGING, DOSE-FINDING, UMBRELLA STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08653945 AND PF-08653944, ALONE OR IN COMBINATION, IN ADULTS WITH OVERWEIGHT OR OBESITY (SOLIS-1)Results expected Q3 2027

Clinical trials

3 sponsors · 1 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme

All trials

Active

Late-stage

Completed

Late-stage studies

A Double Blind, Placebo Controlled, Fixed-Flexible Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

Phase 4 · Completed · Maimonides Medical Center

Recruiting

Phase 2 · Recruiting · Pfizer

Recently completed

A Double Blind, Placebo Controlled, Fixed-Flexible Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

Phase 4 · Completed · Maimonides Medical Center

Pilot Study of the Metabolic Effects of Betahistine Hydrochloride in Overweight Women

Phase 1 · Completed · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time

20042025

Most influential

Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited.

Arteriosclerosis, thrombosis, and vascular biology · 2004 · 863 cites

Reductive stress: The key pathway in metabolic disorders induced by overnutrition.

Journal of advanced research · 2025 · 11 cites

Recent publications

Reductive stress: The key pathway in metabolic disorders induced by overnutrition.

Journal of advanced research · 2025 · 11 cites

Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited.

Arteriosclerosis, thrombosis, and vascular biology · 2004 · 863 cites

Major themes4

Metabolic Diseases1
Models, Biological1
Overnutrition1
Oxidative Stress1

Leading journals2

Arteriosclerosis, thrombosis, and vascular biology1
Journal of advanced research1

Leading researchers8

Ceriello A1
Gao J1
Gao Z1
Motz E1
Wang CY1
Wang N1
Wang X1
Xie H1

Affiliations (unnormalised)3

Experimental and Clinical1
Institute of Translational Medicine1
The Center for Biomedical Research1

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

BANK10.46 CDH70.44 CPNE40.43 MC4R0.43 GALNT100.43 AUTS20.43 ANAPC40.43 ETV50.41 ZNF5360.41 LINGO20.41 LRFN20.40 FAIM20.39

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Melanocortin receptor 4via MC4R0.43

Related conditions

1 match

Diseases frequently studied alongside this one. Number shows shared papers.

Cardiovascular Diseases2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

An imbalanced NUTRITIONAL STATUS resulting from excessive intake of nutrients. Generally, overnutrition generates an energy imbalance between food consumption and energy expenditure leading to disorders such as OBESITY.

Identifiers

MeSHOvernutrition

References & data sources

Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
Related entities are derived from literature co-mention (studied together) — associative, not causal.